PENBRAYA ABCWY Pentavalent Vaccine

In October 2023, the FDA approved use of PENBRAYA, a pentavalent meningococcal vaccine targeting the A, B, C, W, and Y meningococcal serogroups. According to the vaccine’s package insert, the effectiveness of PENBRAYA was determined by one clinical study that compared the antibody responses of meningococcal A, B, C, Y and W-135 in individuals who received PENBRAYA to the same antibody responses in individuals who received TRUMEMBA MenB and meningococcal (serogroups A, C, W and Y) oligosaccharide diphtheria CRM197 conjugate vaccine simultaneously. The manufacturer reported that antibody responses to PENBRAYA were non-inferior to those of TRUMEMBA MenB and meningococcal (serogroups A, C, W and Y) oligosaccharide diphtheria CRM197 conjugate vaccine. There is no information available on the long-term effectiveness of PENBRAYA or how effective this vaccine will be outside of clinical trials. Data is also lacking on the effectiveness of giving PENBRAYA at the same time as other vaccines.²⁸

^{NVIC “Quick Facts” is not a substitute for becoming fully informed about Meningococcal disease, meningitis and the Meningococcal vaccine. NVIC recommends consumers read the more complete information following the "Quick Facts", as well as the vaccine manufacturer product information inserts, and speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child.}